Literature DB >> 32643398

Association of Black Race with Outcomes in COVID-19 Disease: A Retrospective Cohort Study.

Ayodeji Adegunsoye1, Iazsmin Bauer Ventura1, Vladimir M Liarski1.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32643398      PMCID: PMC7640625          DOI: 10.1513/AnnalsATS.202006-583RL

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


× No keyword cloud information.
To the Editor: Coronavirus disease (COVID-19) is an emergent threat to public health resulting from the novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The World Health Organization officially declared COVID-19 as a pandemic on March 12, 2020 (1). Average global COVID-19 mortality is estimated at 4.0% but has varied significantly across countries (2). Inpatient mortality, as high as 28% in early reports from China and Italy, has driven worldwide efforts to identify poor prognostic factors (3, 4). Initial studies suggest older age and male sex are associated with COVID-19 infection and hospital mortality (4–8). Similarly, comorbidities, including hypertension, diabetes, and chronic lung disease, have been associated with poor outcomes (3, 7, 9–11). The U.S. Centers for Disease Control and Prevention provided the first study examining race, which suggested that Black patients were disproportionately overrepresented in hospitalized COVID-19 cases. However, data for COVID-19 mortality and cases not requiring hospitalization were lacking (12). As overrepresentation of Black individuals and other racial/ethnic minorities persists among infected, hospitalized, and deceased COVID-19 patients (13–18), we performed a retrospective cohort analysis to examine the association of race with SARS-CoV-2 infection and outcomes.

Methods

Study design, setting, and data sources

All patients who underwent nasopharyngeal swab and SARS-CoV-2 polymerase chain reaction assays after clinical screening (January 1, 2020 to April, 15, 2020) at the University of Chicago were included in this retrospective analysis. As no privacy-sensitive data were used, patient consent was not required (institutional review board waiver no. IRB20-0520). Survival status was imputed from the most recent electronic medical records. All deidentified data were obtained using the Self-Service cohort discovery tool (SEE Cohorts) from the Center for Research Informatics. Demographic information included age, self-identified sex, ethnicity, race, and partial home zip code. Individuals older than 90 years were assigned a maximum age of 90 for analysis (n = 41); one patient was excluded because of missing sex.

Statistical analysis

Data processing and analysis were performed using R statistical computing software (version 3.6.3; R Foundation for Statistical Computing) and Stata software (2019.R.16; StataCorp). Variable comparisons were determined by two-sided t tests, Mann–Whitney U tests, or chi-square tests as appropriate. Logistic regression models were fitted for outcome assessment in univariate analyses, and results were assessed for robustness to analytical technique by reanalyzing the main outcomes with multivariable logistic regression (using age, sex, ethnicity, and zip code as covariates). Additional sensitivity analyses were performed using Poisson generalized linear models with maximum-likelihood estimation. We performed additional analyses to improve the generalizability of our findings beyond age-specific adjustments in multivariable models. Recognizing that our cohort was skewed toward older patients, we used age proportions from the 2000 U.S. Census to derive an age-adjusted data set (19). Combining SARS-CoV-2 positivity rates with reference-population proportions allowed us to examine observed and expected differences among patients stratified by age group and race. We evaluated the population-derived age-adjusted SARS-CoV-2 infection rates, which enabled the prediction of the largest affected age group in the U.S. population.

Results

Cohort demographics

Of 4,413 individuals in our cohort, 17.8% tested positive, 57.6% were Black, and 24.3% were white (Table 1). SARS-CoV-2–positive individuals were more likely to be male (20.1% vs. 16.5%; P = 0.003), older (52.0 yr vs. 44.5 yr; P < 0.0001), and Black (24.3% vs. 8.9%; P < 0.0001); however, SARS-CoV-2–positive Black patients were disproportionately female (62.5% vs. 51.2%; P = 0.01), which is all consistent with published data (6, 9, 18). Overall mortality differed between Black and non-Black subjects (1.9% vs. 0.8%; P = 0.002).
Table 1.

Demographic summary of patient cohort

 SARS-CoV-2–Positive (n = 785)SARS-CoV-2–Negative (n = 3,628)Total (n = 4,413)
Male313 (20.1)1,242 (79.9)1,555
Female472 (16.5)2,386 (83.5)2,858
Age, yr52.0 ± 17.744.5 ± 18.545.8 ± 8.6
Race   
 Black619 (24.3)1,924 (75.7)2,543
 White75 (7.0)996 (93.0)1,071
 Asian/Mideast Indian16 (8.7)168 (91.3)184
 Native Hawaiian/other Pacific Islander0 (0)6 (100)6
 American Indian or Alaska native0 (0)5 (100)5
 More than once race26 (21.7)94 (78.3)120
 Declined4 (7.3)51 (92.7)55
 Unknown32 (13.0)215 (87.0)247
 Not available13 (7.1)169 (92.9)182
Ethnicity   
 Hispanic or Latino25 (9.8)229 (90.2)254
 Not Hispanic or Latino705 (19.3)2,955 (80.7)3,660
 Declined4 (7.7)48 (92.3)52
 Not available18 (9.1)179 (90.9)197
 Unknown33 (13.2)217 (86.8)250

Definition of abbreviation: SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

Data are n (%) or mean ± standard deviation.

Demographic summary of patient cohort Definition of abbreviation: SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2. Data are n (%) or mean ± standard deviation.

Clinical association of COVID-19 with outcomes

SARS-CoV-2–positive subjects had a higher fatality rate when compared with SARS-CoV-2–negative subjects overall (2.5% vs. 1.2%; P = 0.005) and among those hospitalized (6.0% vs. 1.2%; P < 0.0001). There were no observed sex or racial differences in mortality among all SARS-CoV-2–positive patients in the entire cohort (P = 0.48 and P = 0.34, respectively). Analyses using univariate logistic regression models demonstrated that Black race was associated with SARS-CoV-2 infection (odds ratio [OR], 3.30; 95% confidence interval [95% CI], 2.75–3.97) and hospitalization (OR, 3.77; 95% CI, 2.38–5.99) but not mortality. These results remained consistent in multivariable logistic regression models (OR, 2.16; 95% CI, 1.73–2.70 and OR, 1.51; 95% CI, 1.03–1.05, respectively; Table 2) and in sensitivity analyses with Poisson generalized linear models using maximum-likelihood estimation (data not shown).
Table 2.

Univariate and multivariable logistic regression analyses of SARS-CoV-2 infection and all-cause mortality

 SARS-CoV-2 Infection
Mortality among SARS-CoV-2–Positive
Patient CharacteristicsOdds Ratio (95% CI)Adj Odds Ratio (95% CI)P ValueOdds Ratio (95% CI)Adj Odds Ratio (95% CI)P Value
SARS-CoV-2 infection and mortality*      
 Black race3.30 (2.75–3.97)2.16 (1.73–2.70)<0.0012.46 (0.56–10.69)1.01 (0.20–5.04)0.99
 Age, continuous1.02 (1.01–1.03)1.01 (1.00–1.01)0.011.07 (1.03–1.10)1.05 (1.02–1.09)0.001
 Sex, male1.27 (1.09–1.49)1.01 (0.83–1.22)0.961.52 (0.63–3.71)1.22 (0.48–3.11)0.68
 Ethnicity, Hispanic0.49 (0.32–0.74)1.00 (0.61–1.63)0.990.48
 Zip code, 6061.98 (1.63–2.41)1.20 (0.96–1.52)0.112.02 (0.46–8.79)1.05 (0.22–5.10)0.95
 Hospitalization0.948.29 (2.74–25.05)4.67 (1.46–14.91)0.01
       
SARS-CoV-2 hospitalizations and hospital mortality*      
 Black race3.77 (2.38–5.99)1.51 (1.03–1.05)<0.0010.68 (0.14–3.18)0.68 (0.12–3.72)0.66
 Age, decile1.04 (1.03–1.05)1.04 (1.03–1.05)<0.0011.04 (1.01–1.08)1.04 (1.01–1.08)0.001
 Sex, male1.95 (1.44–2.63)2.25 (1.62–3.13)<0.0011.28 (0.46–3.53)1.34 (0.47–3.84)0.58
 Ethnicity, Hispanic0.48 (0.18–1.3)1.44 (0.46–4.51)0.530.99
 Zip code, 6062.38 (1.53–3.7)1.51 (0.93–2.46)0.100.82 (0.18–3.79)0.72 (0.14–3.81)0.70

Definition of abbreviations: Adj = adjusted/multivariable model with adjustments for covariates; CI = confidence interval; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2.

All P values depicted were for adjusted odds ratios and were two-sided; a level of 0.05 was considered statistically significant.

Adjusted/multivariable models include race, age, sex, ethnicity, partial zip code of residence, hospitalization status, and SARS-CoV-2–positive status.

Denotes geographic boundary roughly equivalent to the city of Chicago.

Univariate and multivariable logistic regression analyses of SARS-CoV-2 infection and all-cause mortality Definition of abbreviations: Adj = adjusted/multivariable model with adjustments for covariates; CI = confidence interval; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2. All P values depicted were for adjusted odds ratios and were two-sided; a level of 0.05 was considered statistically significant. Adjusted/multivariable models include race, age, sex, ethnicity, partial zip code of residence, hospitalization status, and SARS-CoV-2–positive status. Denotes geographic boundary roughly equivalent to the city of Chicago.

Age-adjusted SARS-CoV-2 infection rates in Black and non-Black patients

The SARS-CoV-2 infection rate was 10-fold higher among subjects aged 30–50 years than for those aged 0–18 years (0.05 vs. 0.005; Figure 1). The age-adjusted SARS-CoV-2 positivity rate (0.14) remained higher in Black individuals compared with non-Black individuals (0.19 vs. 0.07).
Figure 1.

Comparison of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection rates. Dot plots of observed and age-adjusted SARS-CoV-2 infection based on race. Observed (circles) and age-adjusted (squares) infection rates in Black (solid circles/squares) and non-Black (open circles/squares) cohort patients.

Comparison of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection rates. Dot plots of observed and age-adjusted SARS-CoV-2 infection based on race. Observed (circles) and age-adjusted (squares) infection rates in Black (solid circles/squares) and non-Black (open circles/squares) cohort patients.

Discussion

Our study examines the association of race with SARS-CoV-2 infection, hospitalization, and mortality among all subjects tested for SARS-CoV-2. These data suggest that Black individuals are more likely to test positive and be hospitalized with SARS-CoV-2; however, we found no difference in mortality for Black individuals versus non-Black individuals. Possible hypotheses for these disproportionally high rates among Black individuals include disparities in predisposing medical conditions, health-insurance status, and access to medical care. Although we adjusted for residential zip code, we were unable to adjust for preexisting inequities of socioeconomic status and other critical social determinants of health, which could account for these findings (17, 20). Crowded home settings, care facilities for the elderly, overrepresentation in lower-wage public-service occupations, and underlying comorbidities could conceivably increase the susceptibility of Black subjects to SARS-CoV-2 infection, raising the pretest probability of death from severe COVID-19. Despite this higher risk, the absence of actual racial differences in mortality may imply that our conceptual categories of race reflect healthcare disparities and environmental risk factors more closely than any perceived biological differences (21). Our study was limited by unavailable data points such as socioeconomic status, health insurance, comorbidities, and medication history, which could have enabled us to test the independent association of these outcomes with Black race and fully assess potential confounders. Although these factors may at least partially account for the observed disparities in infection and hospitalization rates, they are also highly colinear, posing substantial challenges to any risk determination of race as an independent factor in outcomes. In addition, as race and ethnicity are complex socially defined constructs that are inherently imprecise, individually self-identified race may evolve or have different connotations that could impact the reliability of assignment to racial and/or ethnic categories in the larger population (22, 23). In addition, our reliance on the electronic medical record for vital-status verification may have underestimated mortality for patients treated outside of our health system. However, this systemic bias would not be expected to affect our final results. Furthermore, as individuals tend to associate more frequently with others of the same race, socioeconomic status, geographical location, and age, screening close contacts of persons with COVID-19 for SARS-CoV-2 positivity would likely violate statistical assumptions of independence for any associations of race with outcomes. In addition, although most subjects in our cohort were from the greater Chicago area, the proportion of Black individuals in our cohort (57.6%) substantially exceeds that of Chicago (30.1%) and the United States (13.4%) (24). However, as access to care is generally lower for Black individuals, these subjects are likely to be sicker and undergo testing at a higher threshold than white individuals. Importantly, our results, which project a total SARS-CoV-2 infection rate of 140 per 1,000 patients, and mostly affect Black individuals, could guide decision-making in COVID-19 testing and health policy. In conclusion, Black race was associated with SARS-CoV-2 infection and hospitalization. These findings may support the prevalence of racial disparities of health that disproportionately affect Black individuals in the United States.
  14 in total

1.  Age adjustment using the 2000 projected U.S. population.

Authors:  R J Klein; C A Schoenborn
Journal:  Healthy People 2010 Stat Notes       Date:  2001-01

2.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

3.  Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy.

Authors:  Giacomo Grasselli; Alberto Zangrillo; Alberto Zanella; Massimo Antonelli; Luca Cabrini; Antonio Castelli; Danilo Cereda; Antonio Coluccello; Giuseppe Foti; Roberto Fumagalli; Giorgio Iotti; Nicola Latronico; Luca Lorini; Stefano Merler; Giuseppe Natalini; Alessandra Piatti; Marco Vito Ranieri; Anna Mara Scandroglio; Enrico Storti; Maurizio Cecconi; Antonio Pesenti
Journal:  JAMA       Date:  2020-04-28       Impact factor: 56.272

4.  Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.

Authors:  Eli S Rosenberg; Elizabeth M Dufort; Tomoko Udo; Larissa A Wilberschied; Jessica Kumar; James Tesoriero; Patti Weinberg; James Kirkwood; Alison Muse; Jack DeHovitz; Debra S Blog; Brad Hutton; David R Holtgrave; Howard A Zucker
Journal:  JAMA       Date:  2020-06-23       Impact factor: 56.272

5.  Hospitalization and Mortality among Black Patients and White Patients with Covid-19.

Authors:  Eboni G Price-Haywood; Jeffrey Burton; Daniel Fort; Leonardo Seoane
Journal:  N Engl J Med       Date:  2020-05-27       Impact factor: 91.245

6.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

7.  Clinical and demographic characteristics of patients dying from COVID-19 in Italy vs China.

Authors:  Giuseppe Lippi; Camilla Mattiuzzi; Fabian Sanchis-Gomar; Brandon M Henry
Journal:  J Med Virol       Date:  2020-06-02       Impact factor: 20.693

8.  Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis.

Authors:  Jing Yang; Ya Zheng; Xi Gou; Ke Pu; Zhaofeng Chen; Qinghong Guo; Rui Ji; Haojia Wang; Yuping Wang; Yongning Zhou
Journal:  Int J Infect Dis       Date:  2020-03-12       Impact factor: 3.623

9.  Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis.

Authors:  Wei-Jie Guan; Wen-Hua Liang; Yi Zhao; Heng-Rui Liang; Zi-Sheng Chen; Yi-Min Li; Xiao-Qing Liu; Ru-Chong Chen; Chun-Li Tang; Tao Wang; Chun-Quan Ou; Li Li; Ping-Yan Chen; Ling Sang; Wei Wang; Jian-Fu Li; Cai-Chen Li; Li-Min Ou; Bo Cheng; Shan Xiong; Zheng-Yi Ni; Jie Xiang; Yu Hu; Lei Liu; Hong Shan; Chun-Liang Lei; Yi-Xiang Peng; Li Wei; Yong Liu; Ya-Hua Hu; Peng Peng; Jian-Ming Wang; Ji-Yang Liu; Zhong Chen; Gang Li; Zhi-Jian Zheng; Shao-Qin Qiu; Jie Luo; Chang-Jiang Ye; Shao-Yong Zhu; Lin-Ling Cheng; Feng Ye; Shi-Yue Li; Jin-Ping Zheng; Nuo-Fu Zhang; Nan-Shan Zhong; Jian-Xing He
Journal:  Eur Respir J       Date:  2020-05-14       Impact factor: 16.671

10.  Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020.

Authors:  Shikha Garg; Lindsay Kim; Michael Whitaker; Alissa O'Halloran; Charisse Cummings; Rachel Holstein; Mila Prill; Shua J Chai; Pam D Kirley; Nisha B Alden; Breanna Kawasaki; Kimberly Yousey-Hindes; Linda Niccolai; Evan J Anderson; Kyle P Openo; Andrew Weigel; Maya L Monroe; Patricia Ryan; Justin Henderson; Sue Kim; Kathy Como-Sabetti; Ruth Lynfield; Daniel Sosin; Salina Torres; Alison Muse; Nancy M Bennett; Laurie Billing; Melissa Sutton; Nicole West; William Schaffner; H Keipp Talbot; Clarissa Aquino; Andrea George; Alicia Budd; Lynnette Brammer; Gayle Langley; Aron J Hall; Alicia Fry
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-04-17       Impact factor: 17.586

View more
  14 in total

1.  Racial and Ethnic Discrepancy in Pulse Oximetry and Delayed Identification of Treatment Eligibility Among Patients With COVID-19.

Authors:  Ashraf Fawzy; Tianshi David Wu; Kunbo Wang; Matthew L Robinson; Jad Farha; Amanda Bradke; Sherita H Golden; Yanxun Xu; Brian T Garibaldi
Journal:  JAMA Intern Med       Date:  2022-07-01       Impact factor: 44.409

2.  Integrin/TGF-β1 Inhibitor GLPG-0187 Blocks SARS-CoV-2 Delta and Omicron Pseudovirus Infection of Airway Epithelial Cells In Vitro, Which Could Attenuate Disease Severity.

Authors:  Kelsey E Huntington; Lindsey Carlsen; Eui-Young So; Matthias Piesche; Olin Liang; Wafik S El-Deiry
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-17

3.  Characteristics and Outcomes of US Patients Hospitalized With COVID-19.

Authors:  Ithan D Peltan; Ellen Caldwell; Andrew J Admon; Engi F Attia; Stephanie J Gundel; Kusum S Mathews; Alexander Nagrebetsky; Sarina K Sahetya; Christine Ulysse; Samuel M Brown; Steven Y Chang; Andrew J Goodwin; Aluko A Hope; Theodore J Iwashyna; Nicholas J Johnson; Michael J Lanspa; Lynne D Richardson; Kelly C Vranas; Derek C Angus; Rebecca M Baron; Benjamin A Haaland; Douglas L Hayden; B Taylor Thompson; Todd W Rice; Catherine L Hough
Journal:  Am J Crit Care       Date:  2022-03-01       Impact factor: 2.207

4.  Racial Disparities in Pulmonary Fibrosis and the Impact on the Black Population.

Authors:  Ayodeji Adegunsoye; Monica Vela; Milda Saunders
Journal:  Arch Bronconeumol       Date:  2021-10-02       Impact factor: 6.333

5.  A series of COVID-19 autopsies with clinical and pathologic comparisons to both seasonal and pandemic influenza.

Authors:  Phillip McMullen; Peter Pytel; Alexis Snyder; Heather Smith; Jasmine Vickery; James Brainer; Robert Guzy; David Wu; Nathan Schoettler; Ayodeji Adegunsoye; Anne Sperling; John Hart; Lindsay Alpert; Anthony Chang; Sandeep Gurbuxani; Thomas Krausz; Aliya N Husain; Jeffrey Mueller
Journal:  J Pathol Clin Res       Date:  2021-05-07

6.  Assessment of Disparities Associated With a Crisis Standards of Care Resource Allocation Algorithm for Patients in 2 US Hospitals During the COVID-19 Pandemic.

Authors:  Hayley B Gershengorn; Gregory E Holt; Andrew Rezk; Stefanie Delgado; Nayna Shah; Arshia Arora; Leah B Colucci; Belen Mora; Rahul S Iyengar; Andy Lopez; Bianca M Martinez; Joseph West; Kenneth W Goodman; Daniel H Kett; Jeffrey P Brosco
Journal:  JAMA Netw Open       Date:  2021-03-01

7.  Risk of Clinical Severity by Age and Race/Ethnicity Among Adults Hospitalized for COVID-19-United States, March-September 2020.

Authors:  Audrey F Pennington; Lyudmyla Kompaniyets; April D Summers; Melissa L Danielson; Alyson B Goodman; Jennifer R Chevinsky; Leigh Ellyn Preston; Lyna Z Schieber; Gonza Namulanda; Joseph Courtney; Heather M Strosnider; Tegan K Boehmer; William R Mac Kenzie; James Baggs; Adi V Gundlapalli
Journal:  Open Forum Infect Dis       Date:  2020-12-28       Impact factor: 3.835

8.  Accuracy of the Sequential Organ Failure Assessment Score for In-Hospital Mortality by Race and Relevance to Crisis Standards of Care.

Authors:  William Dwight Miller; Xuan Han; Monica E Peek; Deepshikha Charan Ashana; William F Parker
Journal:  JAMA Netw Open       Date:  2021-06-01

9.  Statins and clinical outcomes in hospitalized COVID-19 patients with and without Diabetes Mellitus: a retrospective cohort study with propensity score matching.

Authors:  Prateek Lohia; Shweta Kapur; Sindhuri Benjaram; Zachary Cantor; Navid Mahabadi; Tanveer Mir; M Safwan Badr
Journal:  Cardiovasc Diabetol       Date:  2021-07-10       Impact factor: 9.951

10.  Racial/ethnic disparities in exposure to COVID-19, susceptibility to COVID-19 and access to health care - findings from a U.S. national cohort.

Authors:  McKaylee M Robertson; Meghana Shamsunder; Ellen Brazier; Mekhala Mantravadi; Madhura S Rane; Drew A Westmoreland; Angela M Parcesepe; Rebecca Zimba; Andrew R Maroko; Sarah G Kulkarni; Christian Grov; Denis Nash
Journal:  medRxiv       Date:  2022-01-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.